{
  "docId": "019de073-7a8f-7069-abd7-4f5a253312a5",
  "docSlug": "7534f8dddd85d538a9efc95a5aebf002",
  "documentTitle": "Aquestive Therapeutics | Results Presentation Deck | 14 slides",
  "authorId": "aquestive-therapeutics",
  "authorName": "Aquestive Therapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 7,
  "pageCount": 14,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7a8f-7069-abd7-4f5a253312a5/7",
  "deckHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5",
  "deckJsonHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5.json",
  "deckAnchorHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.06,
        "y": 0.335
      },
      "kind": "chart",
      "text": "Box plot comparing Cmax for IM 0.3mg, EpiPen 0.3mg, and AQST-109 12mg",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bffa40a-12f5-4178-a409-2950694f0476",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.52,
        "y": 0.335
      },
      "kind": "chart",
      "text": "Line chart showing mean baseline adjusted Epi concentrations over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0876501-9ea6-43ac-9dcb-d4102464ae7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "AQST-109 Cmax values within the timeframe critical to abate the cascade of anaphylaxis are comparable to and well bracketed by the 0.3mg IM and the EpiPen®",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9664c713-76dc-4d1a-8e5f-8fbd043b9cda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.06,
        "y": 0.77
      },
      "kind": "source-note",
      "text": "Represents data from top-line results. Geometric means presented for Cmax. EPIPHAST II study was conducted with a 4-minute administration hold time. Administration instructions for future studies may vary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45482a94-7013-4f43-846b-0620da28cca4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.19
      },
      "kind": "title",
      "text": "EPIPHAST II: Topline Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6c92cf0-6baa-4d8b-97c8-a054b8ffbf2c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "22f79f23-decd-40b6-9ea5-c379c7fd9920",
      "evidence": "The slide includes a line chart and a box plot to display data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 3,
      "beatId": "fd64535f-8805-4be0-ab9c-f0396589752f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document provides relief through presentation of EPIPHAST II trial results, including key takeaways and data, on slides 3-13",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b6791be9-182b-48c3-8ddb-65cec4fe9e39",
      "evidence": "The document implies the cost of inaction through presentation of rapid epinephrine delivery and trial results",
      "position": 0,
      "objective": "What is the cost of not using Aquestive Therapeutics' epinephrine product?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}